RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:2 weeks: It’s all it took for Merck to get AA FGPStock ...
Tell us,
- did analyst Uddin had access to TLT management?
- did he had access to the content of discussions between TLT and the FDA?
- why, or under which reason or under what basis, TLT management would have advanced by 30 months this "Commercial revenues (projected)" milestone? Try to respond to this one please.
- did analyst Uddin mentioned that Roche and Merck obtained AA in the bladder indication and why TLT wouldn't qualify for?
- Keytruda is not important to you? Well, it's one of benchmark that serves as a reference to beat!
I can understand why you're calling me a pumper when you come up with poor statements like this one below as you lack basic understanding:
"If Uddin thought AA and revenues were coming in Jan 2023, like you have always projected, I don't think he would have reduced his price target and push back his timelines."
Hummm! I never projected anything. It's just that I work with the info. I find. Better than playing the big executive like you.
It happens that while you were doing nothing in terms of digging, I noticed in April a subtle change in the Feb. TLT's corporate presentation. So I started wondering why such a change and because, contrary to you, I happen to master more information, I found that the only thing that could justify such change was the AA program. Funny that you think digging is pumping, when on your side you're ignorant and not up to date.
Don't hit the door on your way out!